Early Eculizumab Withdrawal in Patients With Atypical Hemolytic Uremic Syndrome in Native Kidneys Is Safe and Cost-Effective: Results of the CUREiHUS Study

INTRODUCTION: The introduction of eculizumab has improved the outcome in patients with atypical hemolytic uremic syndrome (aHUS). The optimal treatment strategy is debated. Here, we report the results of the CUREiHUS study, a 4-year prospective, observational study monitoring unbiased eculizumab dis...

Descripción completa

Detalles Bibliográficos
Autores principales: Bouwmeester, Romy N., Duineveld, Caroline, Wijnsma, Kioa L., Bemelman, Frederike J., van der Heijden, Joost W., van Wijk, Joanna A.E., Bouts, Antonia H.M., van de Wetering, Jacqueline, Dorresteijn, Eiske, Berger, Stefan P., Gracchi, Valentina, van Zuilen, Arjan D., Keijzer-Veen, Mandy G., de Vries, Aiko P.J., van Rooij, Roos W.G., Engels, Flore A.P.T., Altena, Wim, de Wildt, Renée, van Kempen, Evy, Adang, Eddy M., ter Avest, Mendy, ter Heine, Rob, Volokhina, Elena B., van den Heuvel, Lambertus P.W.J., Wetzels, Jack F.M., van de Kar, Nicole C.A.J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9832049/
https://www.ncbi.nlm.nih.gov/pubmed/36644349
http://dx.doi.org/10.1016/j.ekir.2022.10.013

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9832049/
https://www.ncbi.nlm.nih.gov/pubmed/36644349
http://dx.doi.org/10.1016/j.ekir.2022.10.013

Ejemplares similares